title: Final height and IGF1 in adult survivors of Wilms tumour.
abstract: OBJECTIVE
  One-sided nephrectomy is followed by increased levels of IGF1, associated with linear growth during childhood. The aim was to evaluate final height and IGF1 levels in nephrectomized Wilms tumour survivors when compared with healthy Dutch references and survivors of other cancer types.
  
  
  METHODS
  Cross-sectional retrospective study.
  
  
  METHODS
  Data of 575 adult childhood cancer survivors were analysed. median follow-up time was 17.8 (range 5.048.8) years. Analysis of (co)variance was performed to evaluate differences between subgroups: nephrectomized Wilms survivors treated with or without abdominal irradiation (n=41 and n=36) and survivors of other cancer types treated with or without irradiation involving the cranium, abdomen or total body (n=149 and n=349). Main outcome measures were IGF1 and height, expressed as SDS.
  
  
  RESULTS
  After adjustment for age at diagnosis, former corticosteroid treatment and renal impairment, height SDS in non-irradiated nephrectomized Wilms survivors was significantly higher than that in non-irradiated survivors of other cancer types (estimated mean SDS -0.09 vs -0.49, P=0.044), abdominal irradiated survivors (SDS -0.70, P=0.015) and other irradiated survivors (SDS -1.47, P<0.001). Non-irradiated nephrectomized Wilms tumour survivors had significantly higher IGF1 SDS than other irradiated survivors (estimated mean SDS -0.05 vs -1.36, P<0.001 and 0.11 vs 1.37, P<0.001), while there was no significant difference with the other two subgroups.
  
  
  CONCLUSIONS
  Adult survivors of Wilms tumour showed better attainment of final height and relatively higher IGF1 levels than those of other cancer types who had significantly shorter stature and lower IGF1 levels than Dutch references.
authors.affiliation: Department of Paediatric Oncology/Haematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, PO Box 2060, 3000 CB Rotterdam, The Netherlands.
authors.forename: K
authors.initials: K
authors.lastname: Blijdorp
authors.forename: M M
authors.initials: MM
authors.lastname: van den Heuvel-Eibrink
authors.forename: R
authors.initials: R
authors.lastname: Pieters
authors.forename: S M F
authors.initials: SM
authors.lastname: Pluijm
authors.forename: A
authors.initials: A
authors.lastname: Wagner
authors.forename: H
authors.initials: H
authors.lastname: Segers
authors.forename: A J
authors.initials: AJ
authors.lastname: van der Lely
authors.forename: S J C M M
authors.initials: SJ
authors.lastname: Neggers
mesh_terms: D000328:Adult; D001827:Body Height; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000532:radiotherapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D009426:Netherlands; D009929:Organ Size; D012189:Retrospective Studies; D017741:Survivors; D009396:Wilms Tumor / Q000532:radiotherapy / Q000601:surgery*; D055815:Young Adult
chemical_list: D007334:Insulin-Like Growth Factor I